Noah Sather, PhD

Noah Sather, PhD

Infectious Disease Research

Children's Title: Principal Investigator, Supervisor, Center for Global Infectious Disease Research

Academic Title: Associate Professor

Research Center: Center for Global Infectious Disease Research

  • Biography

    Noah Sather, PhD, is an associate professor at the Center for Global Infectious Disease Research. He joined the center in 2015 to advance its programs in vaccine development for HIV-1 and malaria. Sather received his PhD at Wayne State University in biological sciences, where his thesis work focused on a systems analysis to unravel the secrets of developmental biology. He joined the center as a postdoctoral fellow in the laboratory of Dr. Leo Stamatatos, where he worked to understand how anti–HIV-1 antibodies develop.

  • Patient Testimonials

    Be the first to recommend Dr. Noah Sather

  • Awards and Honors

    Award Name Award Description Awarded By Award Date
    Early Career Investigator Fellowship Immune Correlates of HIV Protection 2010
    International Travel Scholarship AIDS Vaccine 2009 2009
    Keystone Symposium Travel Scholarship Keystone Symposium 2009
    Summer Dissertation Fellowship Wayne State University Graduate School 2006
    Thomas C. Rumble Competitive Fellow Wayne State University 2006 - 2007
    Dr. William A Turner Memorial Scholarship Wayne State University 2004
    Graduate Teaching Award, Biological Sciences Wayne State University 2003 - 2005

  • Publications

    Manuscripts in Refereed Journals

    • Fisher BS, Dambrauskas N, Trakhimets O, Andrade DV, Smedley J, Sodora DL, Sather DN.
      Oral Immunization with HIV-1 Envelope SOSIP trimers elicits systemic immune responses and cross-reactive anti-V1V2 antibodies in non-human primates.
      PLoS One, 2020 May 29 : 15(5)e0233577 PMCID:PMC7259690
      https://pmlegacy.ncbi.nlm.nih.gov/pubmed/32470041
    • Doepker LE, Simonich CA, Ralph D, Shipley MM, Garrett M, Gobillot T, Vigdorovich V, Sather DN, Nduati R, Matsen FA 4th, Overbaugh JM.
      Diversity and Function of Maternal HIV-1-Specific Antibodies at the Time of Vertical Transmission
      J Virol., 2020 Apr 16 : 94(9)e01594-19
      https://pubmed.ncbi.nlm.nih.gov/32075936/
    • Puligedda RD, Vigdorovich V, Kouiavskaia D, Kattala CD, Zhao JY, Al-Saleem FH, Chumakov K, Sather DN, Dessain SK.
      Human IgA Monoclonal Antibodies That Neutralize Poliovirus, Produced by Hybridomas and Recombinant Expression
      Antibodies (Basel)., 2020 Feb 28 : 9(1)E5
      https://pubmed.ncbi.nlm.nih.gov/32121092/
    • Simonich CA, Doepker L, Ralph D, Williams JA, Dhar A, Yaffe Z, Gentles L, Small CT, Oliver B, Vigdorovich V, Mangala Prasad V, Nduati R, Sather DN, Lee KK, Matsen Iv FA, Overbaugh J.
      Kappa chain maturation helps drive rapid development of an infant HIV-1 broadly neutralizing antibody lineage.
      Nat Commun, 2019 May 16 : 10(1)2190 PMCID:PMC6522554
      https://www.ncbi.nlm.nih.gov/pubmed/31097697
    • Swearingen KE, Eng JK, Shteynberg D, Vigdorovich V, Springer TA, Mendoza L, Sather DN, Deutsch EW, Kappe SHI, Moritz RL.
      A tandem mass spectrometry sequence database search method for indentification of O-fucosylated proteins by mass spectrometry.
      J Proteome Res, 2019 Feb 1 : 18(2)652-663 PMCID:PMC6445572
      https://www.ncbi.nlm.nih.gov/pubmed/30523691
    • Chukwuma VU, Kose N, Sather DN, Sapparapu G, Falk R, King H, Singh V, Lampley R, Malherbe DC, Ditto NT, Sullivan JT, Barnes T, Doranz BJ, Labranche CC, Montefiori DC, Kalams SA, Haigwood NL, Crowe JE Jr.
      Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth.
      PLoS One, 2018 Dec 19 : 13(12)e0209437 PMCID:PMC6300260
      https://www.ncbi.nlm.nih.gov/pubmed/30566528
    • Arredondo SA, Swearingen KE, Martinson T, Steel R, Dankwa DA, Harupa A, Camargo N, Betz W, Vigdorovich V, Oliver BG, Kangwanrangsan N, Ishino T, Sather N, Mikolajczak S, Vaughan AM, Torii M, Moritz RL, Kappe SHI.
      The micronemal Plasmodium proteins P36 and P52 act in concert to establish the replication-permissive compartment within infected hepatocytes.
      Front Cell Infect Microbiol, 2018 Nov 27 : 8413 PMCID:PMC6280682
      https://www.ncbi.nlm.nih.gov/pubmed/?term=30547015
    • Schaefer C, Dambrauskas N, Steel RW, Carbonetti S, Chuenchob V, Flannery EL, Vigdorovich V, Oliver BG, Roobsoong W, Maher SP, Kyle D, Sattabongkot J, Kappe SHI, Mikolajczak SA, Sather DN.
      A recombinant antibody against Plasmodium vivax UIS4 for distinguishing replicating from dormant liver stages.
      Malar J, 2018 Oct 17 : 17(1)370 PMCID:PMC6192329
      https://www.ncbi.nlm.nih.gov/pubmed/?term=30333026
    • Yacoob C, Lange MD, Cohen K, Lathia K, Feng J, Glenn J, Carbonetti S, Oliver B, Vigdorovich V, Sather DN, Stamatatos L.
      B cell clonal lineage alterations upon recombinant HIV-1 envelope immunization of rhesus macaques.
      PLoS Pathog, 2018 Jun 22 : 14(6)e1007120 PMCID:PMC6033445
      https://www.ncbi.nlm.nih.gov/pubmed/?term=29933399
    • Roth A, Maher SP, Conway AJ, Ubalee R, Chaumeau V, Andolina C, Kaba SA, Vantaux A, Bakowski MA, Thomson-Luque R, Adapa SR, Singh N, Barnes SJ, Cooper CA, Rouillier M, McNamara CW, Mikolajczak SA, Sather DN, Witkowski B, Campo B, Kappe SHI, Lanar DE, Nosten F, Davidson S, Jiang RHY, Kyle DE, Adams JH.
      A comprehensive model for assessment of liver stage therapies targeting Plasmodium vivax and Plasmodium falciparum.
      Nat Commun, 2018 Jun 8 : 9(1)2317 PMCID:PMC5993793
      https://www.ncbi.nlm.nih.gov/pubmed?term=29884783
    • Johnson JS, Lucas SY, Amon LM, Skelton S, Nazitto R, Carbonetti S, Sather DN, Littman DR, Aderem A.
      Reshaping of the dendritic cell chromatin landscape and interferon pathways during HIV-1 Infection.
      Cell Host & Microbe, 2018 Mar 14 : 23(3)366-81 PMCID:PMC6176724
      https://www.ncbi.nlm.nih.gov/pubmed?term=29544097
    • Hahn WO, Butler NS, Lindner SE, Akilesh HM, Sather DN, Kappe SH, Hamerman JA, Gale M Jr., Liles WC, Pepper M.
      cGAS-mediated control of blood-stage malaria promotes Plasmodium-specific germinal center responses.
      JCI Insight, 2018 Jan 25 : 3(2) PMCID:PMC5821207
      https://www.ncbi.nlm.nih.gov/pubmed/?term=29367469
    • Steel RWJ, Pei Y, Camargo N, Kaushansky A, Dankwa DA, Martinson T, Nguyen T, Betz W, Cardamone H, Vigdorovich V, Dambrauskas N, Carbonetti S, Vaughan AM, Sather DN, Kappe SHI.
      Plasmodium yoelli S4/CelTOS is important for sporozoite gliding motility and cell traversal.
      Cellular Microbiology, 2017 Dec 18
      https://www.ncbi.nlm.nih.gov/pubmed/?term=29253313
    • Kessler A, Dankwa S, Bernabeu M, Harawa V, Danziger S, Duffy F, Kampondeni SD, Potchen MJ, Dambrauskas N, Vigdorovich V, Oliver BG, Hochman SE, Mowrey WB, MacCormick I, Mandala WL, Rogerson SJ, Sather DN, Aitchison JD, Taylor TE, Seydel KB, Smith JD, Kim K.
      Linking EPCR-binding PfEMP1 to brain swelling in pediatric cerebral malaria.
      Cell Host & Microbe, 2017 Nov 8 : 22(5)601-614 PMCID:PMC5783720
      https://www.ncbi.nlm.nih.gov/pubmed/?term=29107642
    • Carbonetti S, Oliver BG, Vigdorovich V, Dambrauskas N, Sack BK, Bergl E, Kappe SHI, Sather DN.
      A method for the isolation and characterization of functional murine monoclonal antibodies by single B cell cloning.
      Journal of Immunological Methods, 2017 Sept. : 44866-73 PMCID:PMC5546949
      https://www.ncbi.nlm.nih.gov/pubmed/?term=28554543
    • Carnes J, McDermott S, Anupama A, Oliver BG, Sather DN, Stuart K.
      In vivo cleavage specificity of Trypanosoma brucei editosome endonucleases.
      Nucleic Acids Res, 2017 May 5 : 45(8)4667-4686 PMCID:PMC5416837
      https://www.ncbi.nlm.nih.gov/pubmed/?term=28334821
    • Sack B, Kappe SH, Sather DN.
      Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection.
      Expert Rev Vaccines, 2017 May : 16(5)403-414
      https://www.ncbi.nlm.nih.gov/pubmed/?term=28277097
    • Kublin JG, Mikolajczak SA, Sack BK, Fishbaugher ME, Seilie A, Shelton L, VonGoedert T, Firat M, Magee S, Fritzen E, Betz W, Kain HS, Dankwa DA, Steel RW, Vaughan AM, Noah Sather D, Murphy SC, Kappe SH.
      Complete Attenuation of Genetically Engineered Plasmodium falciparum Sporozoites in Human Subjects
      Sci Transl Med, 2017 Jan 4 : 9(371)
      https://www.ncbi.nlm.nih.gov/pubmed/?term=28053159
    • Nicholas KJ, Flaherty DK, Smith RM, Sather DN, Kalams SA.
      Chronic HIV-1 infection impairs superantigen-induced activation of peripheral CD4+CXCR5+PD-1+cells, with relative preservation of recall antigen-specific responses.
      J Acquir Immune Defic Syndr, 2017 Jan 1 : 74(1)72-80 PMCID:PMC5140753
      https://www.ncbi.nlm.nih.gov/pubmed/?term=27509243
    • Keitany GJ, Kim KS, Krishnamurty AT, Hondowicz BD, Hahn WO, Dambrauskas N, Sather DN, Vaughan AM, Kappe SH, Pepper M.
      Blood stage malaria disrupts humoral immunity to the pre-erythrocytic stage circumsporozoite protein.
      Cell Rep, 2016 Dec 20 : 17(12)3193-3205 PMCID:PMC5476299
      https://www.ncbi.nlm.nih.gov/pubmed/?term=28009289
    • Yacoob C, Pancera M, Vigdorovich V, Oliver BG, Glenn JA, Sather DN, McGuire AT, Stamatatos L.
      Differences in allelic frequency and CDRH3 region limit the engagement of HIV Env immunogens by putative VRC01 neutralizing antibody precursors.
      Cell Rep, 2016 Nov 1 : 17(6)1560-1570 PMCID:PMC5207042
      https://www.ncbi.nlm.nih.gov/pubmed/?term=27806295
    • Vigdorovich V, Oliver BG, Carbonetti S, Dambrauskas N, Lange MD, Yacoob C, Leahy W, Callahan J, Stamatatos L, Sather DN.
      Repertoire comparison of the B-cell receptor-encoding loci in humans and rhesus macaques by next-generation sequencing.
      Clin Transl Immunology, 2016 Jul 22 : 5(7)e93 PMCID:PMC4973324
      https://www.ncbi.nlm.nih.gov/pubmed/?term=27525066
    • Hessell AJ, Malherbe DC, Pissani F, McBurney S, Krebs SJ, Gomes M, Pandey S, Sutton WF, Burwitz BJ, Gray M, Robins H, Park BS, Sacha JB, LaBranche CC, Fuller DH, Montefiori DC, Stamatatos L, Sather DN, Haigwood NL.
      Achieving potent autologous neutralizing antibody responses against Tier 2 HIV-1 viruses by strategic selection of envelope immunogens.
      J Immunol, 2016 Apr 1 : 196(7)3064-3078 PMCID:PMC4797725
      https://www.ncbi.nlm.nih.gov/pubmed/26944928
    • Sampath S, Brazier AJ, Avril M, Bernabeu M, Vidgorovich V, Mascarenhas A, Gomes E, Sather DN, Esmon CT, Smith JD.
      Plasmodium falciparum adhesion domains linked to severe malaria differ in blockade of endothelial protein C receptor.
      Cellular Microbiology, 2015 Dec. : 17(12)1868-1882 PMCID:PMC4661071
      https://www.ncbi.nlm.nih.gov/pubmed/?term=26118955
    • Kaushansky A, Douglass AN, Arang N, Vigdorovich V, Dambrauskas N, Austin LS, Sather DN, Kappe SH.
      Malaria parasites target the hepatocyte receptor EphA2 for successful host invasion.
      Science, 2015 Nov 27 : 350(6264)1089-92 PMCID:PMC4783171
      https://www.ncbi.nlm.nih.gov/pubmed/?term=26612952
    • Voronin Y, Sather N.
      Opening the envelope.
      IAVI Report, 2015 : 19(1)16-19
      https://www.ncbi.nlm.nih.gov/pubmed?term=26043500
    • Keitany S, Sack B, Smithers H, Chen L, Jang I, Sebastian L, Gupta M, Sather DN, Vignali M, Kappe S, Vaughan A, Wang R.
      Immunization of mice with live-attenuated late liver stage-arresting malaria parasites generates protective antibody responses to pre-erythrocytic stages.
      Infection and Immunity, 2014 Dec. : 82(12)5143-5153 PMCID:PMC4249261
      https://www.ncbi.nlm.nih.gov/pubmed/?term=25267837
    • Harupa A, Sack B, Lakshmanan V, Arang N, Douglass A, Oliver BG, Stuart AB, Sather DN, Lindner S, Hybiske K, Torii M, and Kappe S.
      SSP3 is a novel Plasmodium yoelli sporozoite surface protein with a role in gliding motility.
      Infection and Immunity, 2014 Nov. : 82(11)4643-53 PMCID:PMC4249349
      https://www.ncbi.nlm.nih.gov/pubmed/?term=25156733
    • Sather DN, Carbonetti S, Malherbe DC, Pissani F, Stuart AB, Hessell AJ, Mikell I, Kalams SA, Haigwood NL, and Stamatatos L.
      Emergence of broadly neutralizing antibodies and viral co-evolution in two subjects during the early stages of infection with the human immunodeficiency virus type 1.
      J Virol, 2014 Nov. : 88(22)12968-81 PMCID:PMC4249098
      https://www.ncbi.nlm.nih.gov/pubmed?term=25122781
    • Malherbe D, Pissani F, Sather DN, Guo B, Pandey S, Sutton W, Stuart A, Robins H, Park B, Krebs S, Schuman J, Kalams S, Hessell AJ, and Haigwood NL.
      Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.
      J Virol, 2014 Nov. : 88(22)12949-67 PMCID:PMC4249069
      https://www.ncbi.nlm.nih.gov/pubmed/?term=25210191
    • Carbonetti S, Oliver BG, Glenn J, Stamatatos L, Sather DN.
      Soluble HIV-1 Envelope immunogens derived from an elite neutralizer elicit cross-reactive V1V2 antibodies and low potency neutralizing antibodies.
      PLoS One, 2014 Jan 23 : 9(1)e86905 PMCID:PMC3900663
      https://www.ncbi.nlm.nih.gov/pubmed/?term=24466285
    • Diskin R, Sather DN, Klein F, Horwitz JA, Halper-Stromberg A, Marcovecchio PM, Lee T, West AP, Gao H, Seaman MS, Stamatatos L, Nussenzweig MC, Bjorkman PJ.
      Restricting HIV-1 pathways for escape using rationally designed anti-HIV antibodies.
      J Exp Med, 2013 Jun 3 : 210(6)1235-49 PMCID:PMC3674693
      https://www.ncbi.nlm.nih.gov/pubmed?term=23712429
    • Hoot S, McGuire AT, Cohen KW, Strong RK, Hangartner L, Klein F, Diskin, R., Scheid, J.F., Sather DN, Burton D.R., Stamatatos L.
      Recombinant HIV envelope proteins fail to engage germline versions of Anti-CD4bs bNAbs.
      PLoS Pathogens, 2013 Jan. : 9(1)e1003106 PMCID:PMC3536657
      https://www.ncbi.nlm.nih.gov/pubmed/?term=23300456
    • Sather DN, Carbonetti S, Kehayia J, Kraft Z, Mikell I, Scheid J, Klein, F, Stamatatos, L.
      Broadly neutralizing antibodies developed by an HIV+ elite neutralizer exact replication fitness cost to the contemporaneous virus.
      J Virol, 2012 Dec 1 : 86(23)12676-85 PMCID:PMC3497623
      https://www.ncbi.nlm.nih.gov/pubmed/?term=22973035
    • Burgers WA, Manrique A, Masopust D, McKinnon LR, Reynolds MR, Rolland M, Blish C, Chege GK, Curran R, Fischer W, Herrera C, Sather DN.
      Measurements of immune responses for establishing correlates of vaccine protection against HIV.
      AIDS Research and Human Retroviruses, 2012 July : 28(7)641-8 PMCID:PMC3380381
      https://www.ncbi.nlm.nih.gov/pubmed/?term=21861777
    • Klein F, Gaebler C, Mouquet H, Sather DN, Lehmann C, Scheid JF, Kraft Z, Liu Y, Pietzsch J, Hurley A, Poignard P, Feizi T, Morris L, Walker BD, Fätkenheuer G, Seaman MS, Stamatatos L, Nussenzweig MC.
      Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein.
      J Exp Med, 2012 Jun 30 : 209(8)1469-79 PMCID:PMC3409500
      https://www.ncbi.nlm.nih.gov/pubmed/?term=22826297
    • Mikell I, Sather DN, Kalams SA, Altfeld M, Alter G, Stamatatos L.
      Characteristics of the earliest cross-neutralizing antibody response to HIV-1.
      PLoS Pathogens, 2011 Jan 13 : 7(1)e1001251 PMCID:PMC3020924
      https://www.ncbi.nlm.nih.gov/pubmed/?term=21249232
    • Correia BE, Ban YE, Holmes MA, Xu H, Ellingson K, Kraft Z, Carrico C, Boni E, Sather DN, Zenobia C, Burke KY, Bradley-Hewitt T, Bruhn-Johannsen JF, Kalyuzhniy O, Baker D, Strong RK, Stamatatos L, Schief WR.
      Computational design of epitope scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope.
      Structure, 2010 Sep 8 : 18(9)116-26
      https://www.ncbi.nlm.nih.gov/pubmed/?term=20826338
    • Sather DN, and Stamatatos L.
      Epitope specificities of cross-reactive NAbs in HIV+ human plasma.
      Vaccine, 2010 May 26 : 28 Suppl 2B8-12 PMCID:PMC2879344
      https://www.ncbi.nlm.nih.gov/pubmed/?term=20510750
    • Sather DN, Jovanovic M, Golenberg EM
      Functional analysis of B and C class floral organ genes in spinach demonstrates their role in sexual dimorphism.
      BMC Plant Biol, 2010 Mar 12 : 1046 PMCID:PMC2923521
      https://www.ncbi.nlm.nih.gov/pubmed/?term=20226063
    • Blish CA, Sather DN, Sellhorn G, Stamatatos L, Sun Y, Srivistava I, Barnett SW, Cleveland B, Overbaugh J, and Hu S
      Comparative immunogenicity of subtype a human immunodeficiency Virus Type 1 envelope exhibiting differential exposure of conserved neutralization epitopes.
      J Virol, 2010 March : 84(5)2573-84 PMCID:PMC2820908
      https://www.ncbi.nlm.nih.gov/pubmed/?term=20015987
    • Golenberg EM, Sather DN, Hancock LC, Buckley KJ, Villafranco NM, and Bisaro DM.
      Development of a gene silencing DNA vector derived from a broad host range gemini virus.
      Plant Methods, 2009 Jul 2 : 59 PMCID:PMC2713212
      https://www.ncbi.nlm.nih.gov/pubmed/?term=19573239
    • Sather DN, Golenberg EM.
      Duplication of AP1 within the Spinacia oleracea L. AP1/FUL clade is followed by rapid amino acid and regulatory evolution.
      Planta, 2009 Feb. : 229(3)507-21
      https://www.ncbi.nlm.nih.gov/pubmed/?term=19005675
    • Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S, Stamatatos L.
      Factors associated with the development of cross-reactive neutralizing antibodies during HIV-1 infection.
      J Virol, 2009 Jan. : 83(2)757-769 PMCID:PMC2612355
      https://www.ncbi.nlm.nih.gov/pubmed/?term=18987148
    • Sather DN, York A, Pobursky KJ, Golenberg EM
      Sequence evolution and sex-specific expression patterns of the C class floral identity gene, SpAGAMOUS, in dioecious Spinacia oleracea L.
      Planta, 2005 Oct. : 222(2)284-292
      https://www.ncbi.nlm.nih.gov/pubmed/?term=15940462
    • Pfent C, Pobursky KJ, Sather DN, Golenberg EM.
      Characterization of SpAPETALA3 and SpPISTILLATA, B class floral identity genes in Spinacia oleracea, and their relationship to floral dimorphism.
      Development Genes and Evolution, 2005 March : 215(3)132-42
      https://www.ncbi.nlm.nih.gov/pubmed/?term=15660251

  • Presentations

    Presentation Title Event Location Date
    Characterization of a new host receptor interaction for PfTRAP identifies a new site of vulnerability for vaccine design ICOPA 2018 Daegu, South Korea 2018
    Toward rational vaccine design for pre-erythrocytic malaria vaccines Joint International Tropical Medicine Meeting 2017 Bangkok, Thailand 2017
    Deciphering host pathogen interactions to inform vaccine design Wayne State University, Detroit, MI 2017
    Exploring the potential of vaccine-elicited antibodies against the pre-erythrocytic stages of P. vivax malaria to bolster eradication efforts International Conference on P. vivax Research Manaus, Brazil 2017
    Novel antibody-inducing vaccine targets against pre-erythrocytic malaria Joint International Tropical Medicine Meeting 2016 Bangkok, Thailand 2016
    Development of pre-erythrocytic vaccine immunogens to induce protective antibodies against malaria Gordon Research Conference on Malaria Girona, Spain 2015
    Novel antibody-inducing vaccine targets against pre-erythrocytic malaria Fred Hutchinson Cancer Research Center VIDD-invited speaker Seattle, WA 2015
    Repertoire analysis of the B cell receptor-encoding loci in humans and rhesus macaques by next generation sequencing Keystone Symposium- HIV Vaccines Banff, Alberta, Canada 2015
    Development of broadly neutralizing anti-HIV-1 antibodies during natural infection through early epitope acquisition and subsequent antibody maturation Research 4 Prevention Cape Town, South Africa 2014
    B cell receptors containing key structural VRC01-like germline amino acid residues are present in the circulating IgM+ B cell repertoire in outbred rhesus macaques Keystone Symposium- HIV Pathogenesis- Virus vs Host Banff, Alberta, Canada 2014
    HIV-1 gp140 Env immunogens derived from an elite neutralizer elicit conformational V1V2 antibodies and broad, but low potency bNAb responses Keystone Symposium- HIV Vaccines Keystone, CO 2013
    Escape from broadly neutralizing antibodies impacts the fitness of the circulating HIV-1 virus in an elite neutralizer Keystone Symposium- HIV Vaccines Keystone, CO 2012
    Escape from autologous anti-CD4-BS NAbs during natural HIV-1 infection Keystone Symposium- Protection from HIV: Targeted Intervention Strategies Whistler, British Columbia, Canada 2011
    Characteristics of the earliest cross-neutralizing antibody responses in acute infection US-Japan AIDS Panel Awaji Island, Japan 2010
    The earliest cross-neutralizing responses The Search for Broadly Protective Anti-HIV Antibodies NIH/NIAID, Bethesda, MD 2010
    Escape from broadly neutralizing anti-CD4-BS NAbs during HIV-1 infection Keystone Symposium- HIV Vaccines Banff, Alberta, Canada 2010
    Neutralization escape in the context of broadly neutralizing anti-CD4 binding site NAbs during HIV-1 infection AIDS Vaccine 2009 Paris, France 2009
    Determinants of Cross-Reactive Neutralizing Antibody Responses Developed During Natural HIV-1 Infection Keystone Symposium- HIV Immunobiology: From Infection to Immune Control Keystone, CO 2009
    Prevalence of Neutralizing Antibodies targeting the MPER region of the HIV gp41 transmembrane protein in two HIV-infected cohorts Collaboration for AIDS Vaccine Discovery Annual Meeting Seattle, WA 2009
    Factors Associated with the Emergence of Cross-Reactive NAb Responses in HIV-1 Infection Viral Pathogenesis Symposium Fred Hutchinson Cancer Research Center, Seattle, WA 2008
    Evaluation of Cross-Neutralizing Antibody Responses in Acute and Chronic HIV-1 Infected Patients Keystone Symposium - HIV Vaccines: Progress and Prospects Banff, Alberta, Canada 2008
    Sex-specific SpWUSCHEL function and its role in sexual dimorphic development in Spinacia Oleracea L Development 2006 University of Michigan, Ann Arbor, MI 2006
    Sex-specific expression and alternative splicing of SoWUSCHEL are associated with sexual dimorphism in Spinacia Oleracea L Developmental Basis of Evolutionary Change 2005 University of Chicago, Chicago, IL 2005

  • Research Funding

    Grant Title Grantor Amount Award Date
    Kinetics, evolution, and effector function of Fc repertoires during vaccination with native-like Env trimers. - R01AI140951 (Sather) NIH/NIAID $3,035,979 Total Direct Costs Feb. 2019 - Jan. 2024
    Development of a pre-erythrocytic P. vivax vaccine to prevent clinical relapse. - R01AI137234 (Sather) NIH/NIAID $2,328,500 Total Direct Costs Jan. 2019 - Dec 31, 2023
    University of Washington/Fred Hutch Center for AIDS Research (CFAR) - Core I: Immunology Core - P30 AI 027757 (Holmes) NIH/NIAID $263,438 Total Direct Costs Oct. 2018 - May 2023
    Molecular determinants of sporozoite/host cell interactions. - R01 AI 134956 (Kappe) NIH/NIAID $1,000,000 Total Direct Costs July 2018 - June 2022
    Using single cell systems biology to evaluate the role of prior infection in vaccine-induced protection. (Kaushansky/Sather) W.F. Keck Foundation $1,000,000 Total Direct Costs July 2018 - June 2020
    Harnessing oral mucosa vaccination to drive protective HIV antibody responses - R01 DE026336 (Sodora/Sather) NIH/NIDCR $2,468,892 Total Direct Costs July 2016 - May 2021
    Infection-blocking antibody targets for malaria - R01 AI117234 (Sather/Kappe) NIH/NIAID $2,255,414 Total Direct Costs Apr 1, 2016 - Mar 31, 2021

Overview

Research Description

The Sather Lab utilizes state-of-the-art technology to develop novel vaccine immunogens and strategies. In addition, the lab is interested in deciphering the mechanisms of antibody mediated protective immunity by HIV or malaria vaccination. The Sather Lab actively collaborates with scientists from the Fred Hutchinson Cancer Center, Oregon Health and Sciences University, the University of Washington and Vanderbilt University. Read more about the Sather Lab.

Research Focus Area

Genetic Engineering, Genetics, Global Health, HIV/AIDS, Host-Pathogen Interaction, Immunology, Infectious Disease, Malaria, Systems Biology